Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 4, Issue 1
  5. Article
Volume 4, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

Eosinophilic cystitis is a rare inflammatory cystitis of unknown origin. Common symptoms include urinary frequency, urgency, pain, and recurrent urinary tract infections. Currently used treatments include corticosteroids, anti-inflammatory drugs, antihistamines, and antibiotics. Here we present a case of successful treatment of eosinophilic cystitis with mepolizumab.

Case Presentation

A 41-year-old female presented with urinary frequency, urgency, and suprapubic pain. She underwent multiple tests including cystoscopy and biopsy, which revealed a diagnosis of eosinophilic cystitis in 2000. She was initially managed with oral antihistamines and oral steroids. However, over the years her symptoms increased in frequency, intensity, and duration. Montelukast 10 mg daily started which did not show any improvement. In 2017 Mepolizumab 100 mg every 4 weeks started. The patient noted improvement after a few months, and she was tolerating her injections well without side effects and had no further flares of her condition.

Discussion

We present a case of eosinophilic cystitis which was refractory to multiple treatments and responded well to mepolizumab. There are no definite guidelines for the management of EC and there is no curative treatment for this disease. Mepolizumab is an anti-IL-5 monoclonal antibody and the use of mepolizumab in the management of EC that is refractory to treatment have been reported in a few cases. The use of mepolizumab has been described in different diseases associated with eosinophilic inflammation such as severe eosinophilic asthma, eosinophilic esophagitis, eosinophilic chronic obstructive pulmonary disease, and severe nasal polyposis.

Conclusion

Mepolizumab can be considered a treatment option in EC cases refractory to the standard treatment. At this time, larger studies are needed to evaluate the efficacy and safety of mepolizumab in EC.

© 2023 Bentham Science Publishers
© 2023 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/nemj/10.2174/04666230313100005
2023-05-15
2025-01-19

  • From This Site

    /content/journals/nemj/10.2174/04666230313100005
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/4/1/NEMJ-4-1-E130323214558.html?itemId=/content/journals/nemj/10.2174/04666230313100005&mimeType=html&fmt=ahah

References

  1. BrownE.W. Eosinophilic granuloma of the bladder.J. Urol.196083566566810.1016/S0022‑5347(17)65773‑213804922
     [Google Scholar]
  2. van den OudenD. Diagnosis and management of eosinophilic cystitis: A pooled analysis of 135 cases.Eur. Urol.200037438639410.1159/00002018310765067
     [Google Scholar]
  3. MosholtKSS DahlC AzawiNH Eosinophilic cystitis: Three cases, and a review over 10 years.BMJ Case Rep20142014bcr201420570810.1136/bcr‑2014‑205708
     [Google Scholar]
  4. TeegavarapuP. SahaiA ChandraA DasguptaP KhanM. Eosinophilic cystitis and its management.Int J Clin Pract200559335636010.1111/j.1742‑1241.2004.00421.x15857336
     [Google Scholar]
  5. ZamanSR VermeulenTL ParryJ Eosinophilic cystitis: Treatment with intravesical steroids and oral antihistamines.BMJ Case Rep20132013bcr201300932710.1136/bcr‑2013‑009327
     [Google Scholar]
  6. AleemS. AzarA. KumarB. FasanoM.B. TakacsE.B. Successful use of cyclosporine for eosinophilic cystitis in a 64-year old female.J. Allergy Clin. Immunol.20161372AB166AB16610.1016/j.jaci.2015.12.676
     [Google Scholar]
  7. Nucala (mepolizumab) for injection.Research Triangle Park, NC: GlaxoSmithKline2015
     [Google Scholar]
  8. CookeW.D. CookeA.T. Eosinophilic cystitis treatment with benralizumab.J. Allergy Clin. Immunol.20201452AB6710.1016/j.jaci.2019.12.73433102077
     [Google Scholar]
  9. DixitC. BullockT. KahleL. WarrierM. Use of benralizumab in refractory eosinophilic cystitis improves symptoms and reduces bladder eosinophils.J. Allergy Clin. Immunol.20211472AB64AB6410.1016/j.jaci.2020.12.254
     [Google Scholar]
  10. PavordI.D. KornS. HowarthP. BleeckerE.R. BuhlR. KeeneO.N. OrtegaH. ChanezP. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial.Lancet2012380984265165910.1016/S0140‑6736(12)60988‑X22901886
     [Google Scholar]
  11. OrtegaH.G. LiuM.C. PavordI.D. BrusselleG.G. FitzGeraldJ.M. ChettaA. HumbertM. KatzL.E. KeeneO.N. YanceyS.W. ChanezP. Mepolizumab treatment in patients with severe eosinophilic asthma.N. Engl. J. Med.2014371131198120710.1056/NEJMoa140329025199059
     [Google Scholar]
  12. SteinM. CollinsM. VillanuevaJ. KushnerJ. PutnamP. BuckmeierB. FilipovichA. AssaadA. RothenbergM. Anti–IL-5 (mepolizumab) therapy for eosinophilic esophagitis.J. Allergy Clin. Immunol.200611861312131910.1016/j.jaci.2006.09.00717157662
     [Google Scholar]
  13. PavordI.D. ChanezP. CrinerG.J. KerstjensH.A.M. KornS. LugogoN. MartinotJ.B. SagaraH. AlbersF.C. BradfordE.S. HarrisS.S. MayerB. RubinD.B. YanceyS.W. SciurbaF.C. Mepolizumab for eosinophilic chronic obstructive pulmonary disease.N. Engl. J. Med.2017377171613162910.1056/NEJMoa170820828893134
     [Google Scholar]
  14. GevaertP. Van BruaeneN. CattaertT. Van SteenK. Van ZeleT. AckeF. De RuyckN. BlommeK. SousaA.R. MarshallR.P. BachertC. Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis.J. Allergy Clin. Immunol.20111285989995.e8, 810.1016/j.jaci.2011.07.05621958585
     [Google Scholar]
/content/journals/nemj/10.2174/04666230313100005
Loading

  • Article Type:     Case Report
Keyword(s): Biologics; Cystitis; Cystoscopy; Eosinophilic; Mepolizumab; Monoclonal antibody

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test